immatics biotechnologies GmbH (4A3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, immatics biotechnologies GmbH (4A3) has a cash flow conversion efficiency ratio of -0.151x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-60.46 Million ≈ $-70.69 Million USD) by net assets (€399.62 Million ≈ $467.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see immatics biotechnologies GmbH market capitalisation for the company's overall valuation and market capitalisation.
immatics biotechnologies GmbH - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how immatics biotechnologies GmbH's cash flow conversion efficiency has evolved over time, based on yearly financial data.
immatics biotechnologies GmbH Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of immatics biotechnologies GmbH ranked by their cash flow conversion efficiency. Explore immatics biotechnologies GmbH earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Willdan Group Inc
NASDAQ:WLDN
|
0.125x |
|
U.S. Physical Therapy, Inc.
NYSE:USPH
|
0.045x |
|
Orora Ltd
AU:ORA
|
0.082x |
|
Temple Bar Investment Trust
LSE:TMPL
|
0.014x |
|
Welspun Enterprises Limited
NSE:WELENT
|
-0.147x |
|
Petkim Petrokimya Holding AS
IS:PETKM
|
0.023x |
|
Beijing China Sciences Runyu Environmental Technology Co. Ltd.
SHE:301175
|
0.034x |
|
Data 3 Ltd
AU:DTL
|
-2.422x |
Annual Cash Flow Conversion Efficiency for immatics biotechnologies GmbH (2019–2025)
The table below shows the annual cash flow conversion efficiency of immatics biotechnologies GmbH from 2019 to 2025. View latest immatics biotechnologies GmbH stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €484.10 Million ≈ $565.96 Million |
€-176.63 Million ≈ $-206.49 Million |
-0.365x | -32.72% |
| 2024-12-31 | €574.84 Million ≈ $672.05 Million |
€-158.03 Million ≈ $-184.75 Million |
-0.275x | -439.47% |
| 2023-12-31 | €225.08 Million ≈ $263.15 Million |
€18.23 Million ≈ $21.31 Million |
0.081x | -82.76% |
| 2022-12-31 | €213.16 Million ≈ $249.21 Million |
€100.13 Million ≈ $117.06 Million |
0.470x | -88.71% |
| 2021-12-31 | €24.06 Million ≈ $28.13 Million |
€100.13 Million ≈ $117.06 Million |
4.161x | +333.26% |
| 2020-12-31 | €104.26 Million ≈ $121.89 Million |
€100.13 Million ≈ $117.06 Million |
0.960x | +155.26% |
| 2019-12-31 | €-40.84 Million ≈ $-47.74 Million |
€70.97 Million ≈ $82.97 Million |
-1.738x | -- |
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecific… Read more